Gts Securities LLC Akebia Therapeutics, Inc. Call Options Transaction History

Gts Securities LLC

  • $46.5 Billion
  • Q2 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$0.86 - $1.63 $27,606 - $52,323
-32,100 Reduced 51.52%
30,200 $30,000
Q1 2024

May 15, 2024
SELL
$1.27 - $2.24 $25,019 - $44,128
-19,700 Reduced 24.02%
62,300 $114,000
Q4 2023

Feb 14, 2024
BUY
$0.8 - $1.28 $2,240 - $3,584
2,800 Added 3.54%
82,000 $101,000
Q3 2023

Nov 15, 2023
BUY
$0.87 - $1.84 $68,904 - $145,728
79,200 New
79,200 $90,000

Others Institutions Holding AKBA

# of Institutions
110
Shares Held
55.3M
Call Options Held
554K
Put Options Held
246K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $245M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email